Pharmamar’s vice president is concerned with the Novavax vaccine

Vice President on Pharmacist, Pedro Fernandez Bridgeachieved a milestone in September 2020 for the group it leads, Zendal: being the manufacturer of the American pharmaceutical company’s coronavirus vaccine Novavax.

Zendal, through biopharmaceuticals biomaterialprepared in a few months for its four factories located in O Porriño, Pontevedra, to address, as soon as the marketing authorizations have arrived, the manufacture of up to 500 million doses of the serum against Covid-19.

The problems came with the multiple delays that occurred with Novavax investigations, although the end result is a 90 percent efficacy against the virus.

The slow evolution of studies led to the approval of the sale of the vaccine in the European Union, a market which Zendal expected to supply up to 250 million doses, to reach the end of 2021 with the vast majority of the European Union’s population. The Old Department has already been vaccinated with at least 2 doses.

Vice President of Pharmacy adhering to the fact that they could put the Novavax medicine into the hole left Janssen Y astrogenbut the data currently handled is that between Pfizer Y modern accounted for 85 percent of direct sales.

Still without US approval

The vaccine was opening up to other markets, however still without US FDA approval. Japan is the last market where it received the sales authorization, but the problem comes back with its penetration ability and Zendal will not be a manufacturer for this territory.

Bankinter’s analysts, while acknowledging the positive news, point to the fact that it is not allowed in the United States, and summarize the situation: “We believe this vaccine is late for a market that is showing signs of shrinkage and, in addition, will have to compete against Pfizer and Moderna”.

Investors are also of this opinion and reach for profits. LShares of Novavax are down 60 percent so far this yearup to 53.48 euros per share, indicating with their operations that they entered the company with the hope of getting their vaccine and avoiding the business.

At the level of results, Novavax closed 2021 raising its revenue to $ 1,146.29 million, from 475.6 million a year ago, thanks to the vaccine, but net losses rose to 1,743.75 million, from 418.26 million in 2020.

The consensus is confident

Instead, the market consensus understands that the current profit construction is explained by the value performance in 2020. The pandemic year titles started over $ 4.5 to close the course above $ 115, indicating a revaluation of more than $ 2,700. percent.

Experts believe that there is room for Novavax and still give it 260 percent capacity and believe that it can reach up to $ 194.67 in 12 months and therefore does not register any sale recommendation and the vast majority of the panel of experts compiled by Bloomberg recommend taking jobs.

Analysts are sticking to facts similar to the one known this week, which has been announced by Pharmamar’s vice president partners The vaccine they developed against the flu and Covid-19 stimulate a strong immune response and may reduce the total amount of antigens by up to 50 percent.

Asylum Vice President of Pharmacy

These are the results of a phase 1-2 study, so there are months, even years, until the study is completed to apply for marketing authorization.

The victory could translate into a new deal for Fernández Puentes, but for now, the number 2 Pharmamar asylum in agreement to develop and manufacture tuberculosis vaccine.

The studies are making positive progress and Zendal has guaranteed that the serum will be effective in more than 70 countries in Southeast Asia and sub – Saharan Africa, where more cases of the pathology occur.

● Send news from finance.com for its social networks: Twitter | Facebook | LinkedIn | flip board. Also in your messaging app: Telegram